The InsidesTM Company's first product, The InsidesTM Systemfi, is a CE-marked medical device that enables chyme and its nutritional contents to be refed into the distal intestine, rather than being discarded from the patient's ostomy appliance.
The InsidesTM Systemfi has been granted "Breakthrough Device Designation" by the US FDA. The InsidesTM Systemfi is now commercially available in the United Kingdom, Europe, and New Zealand. *The InsidesTM Systemfi is not currently approved for sales in the United States. Caution - Investigational Device, Limited by Federal Law to Investigational Use
*The InsidesTM Systemfi is not currently approved for sales in the United States.
Caution - Investigational Device, Limited by Federal Law to Investigational Use
The InsidesTM Company is founded by world-leading pioneers in gut nutrition, and commercialised by med-tech veterans. The InsidesTM Systemfi is now being used in multiple key international intestinal failure sites.
Please contact us today to learn about how our device can impact your patient's journey to recovery.
Professor Ian Bisset
Co-Founder & Chief Medical Officer
Associate Professor
Greg O’Grady
Co-Founder & Chief Scientific Officer
“The InsidesTM Systemfi is revolutionising recovery times & patient well-being.”
*The InsidesTM Systemfi is not currently approved for sales in the United States.
Caution - Investigational Device, Limited by Federal Law to Investigational Use
Under the standard care pathway, patients recovering from colorectal surgery resulting from Colorectal Cancer, and Inflammatory Bowel Disease will have an enterostomy created to divert intestinal contents
(chyme) away from the surgical site (anastomosis) as it heals.
The enterostomy is typically left open for 6-12 months, and during this time, the chyme that is collected is disposed into the toilet. This results in complications, readmissions, and reduced quality of life.
The InsidesTM Company’s first product, The InsidesTM Systemfi, is a chyme reinfusion solution, which enables diverting enterostomy, and enterocutaneous patients to reinfuse chyme (the contents of their ostomy appliance), back into their intestine, allowing them to recommence oral feeding and reduce length of stay in hospital.
.gif)
Earlier return to oral feeding1-2
Patients able to recommence oral feeding
Improved nutritional outcome2
Increase in nutritional risk index by 10.9 (± 9.5) with a 85% reduction in intestinal losses
Improved restoration of gut function3
Reverse gut atrophy and inflammation and improved gut microbiome
Improved renal function4
Prevents dehydration and reduces the potential for chronic kidney disease
Improved liver function5
53% reduction in plasma liver test abnormalities
Wean off Parenteral Nutrition2
>91% of patients weaned off parenteral nutrition within a median of 2 days (± 9)
Emma Ludlow
Clinical Nurse Specialist Ostomy
"The InsidesTM Systemfi allows me to support, and optimise my patient’s journey to recovery."
